← Back to all trials
Completed
NCT05563389
Statin Impact on Hepatic Decompensation
Conditions: Quality of Life, the Incidence of Whole Complications Resultant From Decompensated Liver
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE2, PHASE3
Enrollment: 100
Sponsor: Tanta University
Location: Tanta University Tanta
Summary
The study aims to evaluate the impact of statin on hepatic decompensation.
Eligibility Criteria
Admissibility measures were age ranged from 18 to 75, with a medical diagnosis of decompensated liver cirrhosis built on standard clinical symptoms, laboratory tests, imaging appearances and/or liver biopsy. Decompensation of the disease was labeled by to the lowest degree having one episode of severe complications, including ascites, SBP, jaundice, EGVB and HE.8 All participants were ready to be enrolled and had signed up the informed consent.
The foremost exclusion criteria involved the following: (1) life-deadly leukocytopenia (WBCs \< 1 × 109/l); (2) Pregnant women or lactating mother; (3) patients diagnosed to have primary or secondary liver cancer.
Source: ClinicalTrials.gov (NCT05563389). StuddyBuddy aggregates publicly available trial information.
